

<http://www.es CRS.org/EVENTS/08berlin/freepaperlisting.asp?title=New%20IOLs%20-%206%20Minutes&id=2145&day=17/09/2008&venue=Hall%201>

**First clinical experience with the new bifocal intraocular lens, MS 612
Diffractiva, HumanOptics**

Presenting Author: D.Holland GERMANY

Co Author(s):

D. Uthoff

Purpose: The aim of the retrospective study was to document the safety and efficacy of MS 612 Diffractiva, HumanOptics.

SETTING: Eye Hospital Bellevue, Kiel, Germany.

METHODS: Since August 2007, 9 patients were implanted in both eyes bifocal IOLs (MS 612 Diffractiva HumanOptics, Erlangen, Germany) and in 2 patients only in one eye. In a single case, MIOL of another type was implanted in the partner eye. In the other patient due to the higher astigmatism, toric intraocular lens (tIOL) was implanted in the capsular bag, and a multifocal add-on lens was additionally implanted into the sulcus. Overall we implanted 20 IOLs in 11 patients.

RESULTS: Preoperatively, the median subjective equivalent refraction was -1.25 D (+2.25 to -9.5 D) with a cylinder -1.0 D (0- to -2.75 D). Postoperatively, the median subjective spherical equivalent refraction was +0.25 D (+0.5 to -0.5 D) with a cylinder -0.5 D (0.0 to -1.0 D). The Postoperative distance vision sc in median was 0.8, the near vision sc median was J1. All IOLs were centered. No intra- and postoperative complications were seen. All patients exhibited spectacle free functional vision.

CONCLUSIONS: The MS 612 Diffractiva could be implanted without any difficulty and showed a good centration overtime. It provides good uncorrected visual acuity for distance and near vision. Further investigations, concerning contrast sensitivity and visual acuity in the intermediate zone, glare and halos as well as patient satisfaction overall are under investigation.